Shire ends Sanfilippo A program, venture investing

In its 3Q16 earnings report, Shire plc (LSE:SHP; NASDAQ:SHPG) said it will terminate development of SHP610 after it missed the primary endpoint of a Phase IIb study to treat mucopolysaccharidosis IIIA (MPS IIIA, Sanfilippo A syndrome). Shire said the candidate failed to slow cognitive decline in pediatric patients.

SHP610, a recombinant human N-sulfoglucosamine sulfohydrolase (SGSH; HNS), has Orphan Drug designation in the U.S. and EU for the indication. ...